Abstract
Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits.
| Original language | English (US) |
|---|---|
| Article number | e3003701 |
| Pages (from-to) | 1-4 |
| Number of pages | 4 |
| Journal | PLoS biology |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- General Neuroscience
- General Immunology and Microbiology
- General Biochemistry, Genetics and Molecular Biology
- General Agricultural and Biological Sciences
Fingerprint
Dive into the research topics of 'Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver